These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 3032470)

  • 1. Extensive stage small cell carcinoma of the bronchus. A randomised study of etoposide given orally by one-day or five-day schedule together with intravenous adriamycin and cyclophosphamide.
    Mead GM; Thompson J; Sweetenham JW; Buchanan RB; Whitehouse JM; Williams CJ
    Cancer Chemother Pharmacol; 1987; 19(2):172-4. PubMed ID: 3032470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Randomised phase II study evaluating oral combination chemotherapy (CCNU, cyclophosphamide, etoposide) and intravenous chemotherapy as second-line treatment for relapsed small cell bronchial carcinoma (Trial GFPC0501)].
    Gervais R; Le Guen Y; Le Caer H; Paillotin D; Chouaid C;
    Rev Mal Respir; 2007 May; 24(5):653-8. PubMed ID: 17519820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Five-day oral etoposide treatment for advanced small-cell lung cancer: randomized comparison with intravenous chemotherapy.
    Souhami RL; Spiro SG; Rudd RM; Ruiz de Elvira MC; James LE; Gower NH; Lamont A; Harper PG
    J Natl Cancer Inst; 1997 Apr; 89(8):577-80. PubMed ID: 9106647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomised trial of low-dose/high-frequency chemotherapy as palliative treatment of poor-prognosis small-cell lung cancer: a Cancer research Campaign trial.
    James LE; Gower NH; Rudd RM; Spiro SG; Harper PG; Trask CW; Partridge M; Ruiz de Elvira MC; Souhami RL
    Br J Cancer; 1996 Jun; 73(12):1563-8. PubMed ID: 8664131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective study of etoposide scheduling in combination chemotherapy for limited disease small cell lung carcinoma.
    Abratt RP; Willcox PA; de Groot M; Goodman HT; Jansen ER; Salton DG
    Eur J Cancer; 1991; 27(1):28-30. PubMed ID: 1849413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concurrent cisplatin, prolonged oral etoposide, and vincristine plus chest and brain irradiation for limited small cell lung cancer: a phase II study of the Southwest Oncology Group (SWOG-9229).
    Thomas CR; Giroux DJ; Stelzer KJ; Craig JB; Laufman LR; Taylor SA; Goodwin JW; Crowley JJ; Livingston RB
    Int J Radiat Oncol Biol Phys; 1998 Mar; 40(5):1039-47. PubMed ID: 9539558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cisplatin/etoposide versus ifosfamide/etoposide combination chemotherapy in small-cell lung cancer: a multicenter German randomized trial.
    Wolf M; Havemann K; Holle R; Gropp C; Drings P; Hans K; Schroeder M; Heim M; Dommes M; Mende S
    J Clin Oncol; 1987 Dec; 5(12):1880-9. PubMed ID: 2824710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prolonged, alternating chemotherapy for extensive small cell lung cancer. A Southwest oncology Group study.
    Livingston RB; Crowley JJ; Thompson T; Williamson SK; Meyers FJ; O'Rourke T; Neefe JR
    Cancer; 1993 Jun; 71(11):3509-13. PubMed ID: 8387881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, controlled phase III study of cyclophosphamide, doxorubicin, and vincristine with etoposide (CAV-E) or teniposide (CAV-T), followed by recombinant interferon-alpha maintenance therapy or observation, in small cell lung carcinoma patients with complete responses.
    Tummarello D; Mari D; Graziano F; Isidori P; Cetto G; Pasini F; Santo A; Cellerino R
    Cancer; 1997 Dec; 80(12):2222-9. PubMed ID: 9404698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Etoposide combined with cyclophosphamide plus vincristine compared with doxorubicin plus cyclophosphamide plus vincristine and with high-dose cyclophosphamide plus vincristine in the treatment of small-cell carcinoma of the lung: a randomized trial of the Bristol Lung Cancer Study Group.
    Hong WK; Nicaise C; Lawson R; Maroun JA; Comis R; Speer J; Luedke D; Hurtubise M; Lanzotti V; Goodlow J
    J Clin Oncol; 1989 Apr; 7(4):450-6. PubMed ID: 2538577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Etoposide in the treatment of small-cell lung cancer].
    Ueoka H
    Gan To Kagaku Ryoho; 1996 Dec; 23(14):1920-4. PubMed ID: 8978798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cisplatin, doxorubicin, cyclophosphamide, and etoposide combination chemotherapy for small-cell lung cancer.
    Aisner J; Whitacre MY; Budman DR; Propert K; Strauss G; Van Echo DA; Perry M
    Cancer Chemother Pharmacol; 1992; 29(6):435-8. PubMed ID: 1314712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: a randomized phase III study of the Cancer and Leukemia Group B.
    Miller AA; Herndon JE; Hollis DR; Ellerton J; Langleben A; Richards F; Green MR
    J Clin Oncol; 1995 Aug; 13(8):1871-9. PubMed ID: 7636529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer.
    Slevin ML; Clark PI; Joel SP; Malik S; Osborne RJ; Gregory WM; Lowe DG; Reznek RH; Wrigley PF
    J Clin Oncol; 1989 Sep; 7(9):1333-40. PubMed ID: 2549204
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II trial of cisplatin and irinotecan alternating with doxorubicin, cyclophosphamide and etoposide in previously untreated patients with extensive-disease small-cell lung cancer.
    Tabata M; Kiura K; Okimoto N; Segawa Y; Shinkai T; Yonei T; Kuyama S; Harita S; Hotta K; Ueoka H; Tanimoto M
    Cancer Chemother Pharmacol; 2007 Jun; 60(1):1-6. PubMed ID: 17393168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of limited small-cell lung cancer with etoposide and cisplatin alternating with vincristine, doxorubicin, and cyclophosphamide versus concurrent etoposide, vincristine, doxorubicin, and cyclophosphamide and chest radiotherapy: a Southwest Oncology Group Study.
    Goodman GE; Crowley JJ; Blasko JC; Livingston RB; Beck TM; Demattia MD; Bukowski RM
    J Clin Oncol; 1990 Jan; 8(1):39-47. PubMed ID: 2153194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extensive-stage small-cell bronchogenic carcinoma: intensive induction chemotherapy with high-dose cyclophosphamide plus high-dose etoposide.
    Johnson DH; Wolff SN; Hainsworth JD; Porter LL; Grosh WW; Hande KR; Greco FA
    J Clin Oncol; 1985 Feb; 3(2):170-5. PubMed ID: 2981981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alternating chemotherapy with cyclophosphamide, doxorubicin, vincristine and cisplatin, etoposide followed by prophylactic cranial and thoracic irradiation for small cell lung cancer (SCLC): long-term results.
    Ardizzoni A; Fusco V; Pennucci C; Baldini E; Orsatti M; Vitale V; Bonavia M; Baracco F; Mereu C; Rosso R
    Anticancer Res; 1991; 11(2):681-4. PubMed ID: 1648333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Experience of a German multicenter study group with ifosfamide in small cell lung cancer.
    Havemann K; Wolf M; Drings P; Hans K; Schroeder M; Holle R; Flechtner H; Goerg R; Becker H
    Semin Oncol; 1989 Feb; 16(1 Suppl 3):9-18. PubMed ID: 2539648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Small cell lung cancer (SCLC): a randomized trial of cyclophosphamide, adriamycin, vincristine plus etoposide (CAV-E) or teniposide (CAV-T) as induction treatment, followed in complete responders by alpha-interferon or no treatment, as maintenance therapy.
    Tummarello D; Graziano F; Mari D; Cetto G; Pasini F; Antonio S; Isidori P; Gasparini S
    Anticancer Res; 1994; 14(5B):2221-7. PubMed ID: 7840527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.